A Phase 2 interventional study of FOLFOX and CarboP-pacliT in Esophageal Neoplasms and Gastro-esophageal Junction Cancer, sponsored by Centre Oscar Lambret. Completed at 10 sites in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-03-18.
Sponsored by Centre Oscar Lambret · Phase 2, Interventional, and Treatment
Resectable esophageal or junctional cancer requires medical treatment by radiotherapy and chemotherapy followed by surgery. Currently, one of the most commonly used chemotherapy treatment is the FOLFOX. It is a combination of three drugs administered intravenously: fluorouracil, oxaliplatin and folinic acid. This is the standard treatment.
Another protocol of chemotherapy is widely used by certain European and American teams, due to promising results : a combination of two drugs administered intravenously: Paclitaxel and Carboplatin (CarboP-pacliT). At present, no clinical study has shown the superiority of one treatment over the other.
The objective of this Phase II study is to clarify clinical practice by comparing these two chemotherapy treatments.
There is no standard preoperative (neoadjuvant) chemoradiation (NCRT) regimen for resectable esophageal cancer, because most if all trials failed to show any survival advantage favoring pCRT when compared to surgery only. This failure had been related to the lack of power of some trials, as well as the ability of chemoradiation to potentiate post-operative morbidity (including mortality), and therefore hampering the accrual of its own survival benefit. Hopefully, meta-analyses showed that NCRT increases survival when compared to surgery only. However, in the clinical practice, this does not make easier the choice of the best NCRT treatment. It appeared that the radiation regimen that were used in each randomized trials were heterogeneous with respect with dose, fraction, length of treatment, fields, dosimetry planning, and quality control. This applies also to chemotherapy with respect with the kind of cytotoxics that were used (including number of drugs), as well as dosage, and the number of cycles, although most of the time cytotoxics were fluorouracil and cisplatin.
Dutch colleagues recently showed that NCRT with weekly carboplatin and paclitaxel increase survival, without increasing postoperative mortality. Of note, most tumors in this trial arose from the lower third of the esophagus and esogastric junction and these habitually correlate with less postoperative morbidity compared to upper third tumors. Moreover, the lung volume spared from radiation was greater in junctional tumors than in upper third cancers - a critical point in the development of radiation-induced pneumonitis and subsequent postoperative mortality. It is difficult to understand how this taxane-based chemotherapy is active, as it did not make better that fluorouracil-based regimen in non-operable patients, and as NCRT with taxanes makes radiation-induced pneumonitis more likely. The favorable impact of this NCRT may lie on its radiation regimen. A moderate total dose of radiation, smaller radial margins than in other trials and modern dosimetry with 3D-planning all improve the safety of treatment and of subsequent surgery. Finally, the favorable impact of the Dutch NCRT regimen may lies on the fact that it does not include cisplatin, a compound which has been found related to the occurrence of more sudden deaths than a non cisplatin-based regimen such as the FOLFOX combination (fluorouracil, oxaliplatin, folinic acid) in the setting of definitive chemoradiotherapy.
Our aim is to evaluate the short-term benefit (complete resection rate) and safety (severe postoperative rate) of 2 preoperative regimen, (carboplatin-paclitaxel or fluorouracil-oxaliplatin-folinic acid), combined to the Dutch radiation backbone, in operable esophageal and junctional (Siewert I-II) cancer. The present trial offers the unique opportunity to compare two therapeutic strategies that have already been shown to be efficient in large randomized controlled trials offering level-1 evidence.
1,593 studies on the registry are indexed under Esophageal Neoplasms; 461 are open to participants now.
This study's enrollment of 106 is above the median of 58 across 1,171 interventional studies indexed under Esophageal Neoplasms.
Browse Esophageal Neoplasms studies →Centre Oscar Lambret is the lead sponsor of 127 studies on the registry; 13 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Patient who present with:
Adequate bone marrow reserve, normal renal and liver functions:
Exclusion Criteria:
* Fluorouracil 400 mg/m², IV bolus dose on day 1, followed by continuous IV infusion of fluorouracil 1600 mg/m² over 2 days * Oxaliplatin 85 mg/m², 2-hr IV infusion on day 1 * Folinic acid 200 mg/m² 2-hr IV infusion on day 1 * 3 cycles, q14
Drug: FOLFOX
* Carboplatin (carboP) AUC=2, given by intravenous infusion * Paclitaxel (pacliT) 50 mg/m², given by intravenous infusion * on days 1, 8, 15, 22 and 29
Drug: CarboP-pacliT
radiochemotherapy before surgery
Also known as: Fluorouracil, Oxaliplatin, Folinic acid, Elvorine
radiochemotherapy before surgery
Also known as: Carboplatine, paclitaxel
Short-term benefit of 2 preoperative regimen: complete resection rate AND severe (grade ≥ 3) postoperative morbidity/mortality according to the Clavien-Dindo classification
Complete resection rate (R0, that is "complete removal of all tumor with microscopic examination of margins showing no tumor cells") AND severe (grade ≥ 3) postoperative morbidity/mortality according to the Clavien-Dindo classification. Severe postoperative complication is defined by grade ≥III per-operative or post-operative complication occurring in the 30 days after surgery.
Time frame: up to 30 days after surgery
Rate of completion of full treatment without modification
Time frame: up to 58 days
Evaluation of the efficacy of both regimen in term of overall survival
Overall survival using Kaplan-Meier method
Time frame: From date of inclusion until the date of death from any cause assessed up to 36 months after the last surgery
Evaluation of the efficacy of both regimen in term of disease-free survival
Disease-free survival using Kaplan-Meier method
Time frame: From date of inclusion until the date of first documented progression whichever came first, assessed up to 36 months after the last surgery
Evaluation of the safety of the evaluated regimens in terms of preoperative mortality.
Preoperative mortality (grade 5) rate, according to NCI-CTCAE v4.0 criteria
Time frame: From registration to surgery
Evaluation of the safety of the evaluated regimens in terms of preoperative morbidities, postoperative morbidities, respiratory morbidities.
Pre-operative morbidities according to NCI-CTCAE v4.0 criteria, post-operative morbidities occurring in the 30 days after surgery with the main post-operative complication graded according to Clavien-Dindo, post-operative morbidities occurring more than 30 days after surgery graded according to NCI-CTCAE V4.0, postoperative respiratory morbidity rate according to the Clavien-Dindo classification.
Time frame: From start of treatment to end of study
Evaluation of the efficacy of both regimen in term of Pathological response rate
Complete pathological response (ypCR) rate
Time frame: Surgery
Evaluation of the efficacy of both regimen in term of quality of life
Quality of life: QLQC30 and OES18
Time frame: Up to 3 years after surgery
DVH (CoDose-Volume-Histogram (DVH) and postoperative respiratory morbidity
Time frame: up to 30 days after the beginning of radiotherapy
Comparison of both arms in terms of safety and efficacy
Evaluation of preoperative mortality (grade 5) rate according to NCI-CTCAE v4.0 criteria, pre-operative morbidities according to NCI-CTCAE v4.0 criteria, post-operative morbidities occurring in the 30 days after surgery with the main post-operative complication graded according to Clavien-Dindo, post-operative morbidities occurring more than 30 days after surgery graded according to NCI-CTCAE V4.0, postoperative respiratory morbidity rate according to the Clavien-Dindo classification. Evaluation of overall survival and disease-free survivalusing Kaplan-Meier method, complete pathological response (ypCR) rate
Time frame: From date of inclusion until the date of death from any cause assessed up to 36 months after the last surgery
Net treatment benefit estimation
To estimate the net treatment benefit, combining efficacy and safety endpoints, using the Generalized Pairwise Comparisons Method - GPC method (Buyse, 2010)
Time frame: From date of inclusion until the date of death from any cause assessed up to 36 months after the last surgery
Prognostic factor and treatment effect controlling for possible confounding factors
To identify prognostic factors associated to disease-free survival, and evaluate the treatment effect controlling for possible confounding factors. Following factors will be studied: pre-therapeutic stage (II versus III), pre-therapeutic N (positive versus negative), post-surgery stage (ypT0N0 versus other), TRG (1-2 versus other) and resection (R0 versus other).
Time frame: From date of inclusion until the date of first documented progression whichever came first, assessed up to 36 months after the last surgery
Plan to share: No
This study is completed, as verified in Mar 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Centre Oscar Lambret